SELLAS Reports Q3 2026 Results, GPS Phase 3 Data Expected This Month
SELLAS Life Sciences reported Q3 2026 financial results, noting ERP49 (Galinpepimut-S) topline results are expected soon. The company holds $134.7M in cash and provided corporate updates including continued enrollment in Phase 2 SLS009 trials.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed